Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

miR-221 LNA inhibitor LNA-i-miR-221

A phosphorothioate (PS) modified backbone 13-mer locked nucleic acid (LNA)-based antisense oligonucleotide (ASO) and inhibitor of the oncogenic microRNA (miRNA) miR-221, with potential chemo-sensitizing and antineoplastic activities. Upon administration, miR-221 LNA inhibitor LNA-i-miR-221 hybridizes with endogenous miR-221 and inhibits miR-221-mediated functions involving tumor cell proliferation, angiogenesis and metastasis, and the modulation of drug influx-efflux transporters as it regulates the expression of a variety of target genes. miR-221, oncogenic miRNA that is upregulated in various malignancies, plays important roles in tumor cell proliferation, angiogenesis and metastasis, and in the development of drug resistance such as melphalan resistance.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:LNA-i-miR-221
miR-221 LNA ASO LNA-i-miR-221
miR-221 locked nucleic acid-based antisense oligonucleotide LNA-i-miR-221
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search